AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companyâs flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
äŒæ¥ã³ãŒãAIM
äŒç€ŸåAIM ImmunoTech Inc
äžå Žæ¥Jul 12, 1996
æé«çµå¶è²¬ä»»è
ãCEOãEquels (Thomas K)
åŸæ¥å¡æ°21
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 12
æ¬ç€Ÿæåšå°2117 Sw Highway 484
éœåžOCALA
蚌åžååŒæNASDAQ OMX â NASDAQ Basic Amex
åœUnited States of America
éµäŸ¿çªå·32801
é»è©±çªå·13524487797
ãŠã§ããµã€ãhttps://aimimmuno.com/
äŒæ¥ã³ãŒãAIM
äžå Žæ¥Jul 12, 1996
æé«çµå¶è²¬ä»»è
ãCEOãEquels (Thomas K)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã